niacinamide has been researched along with tenapanor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fouque, D; Ketteler, M; Vervloet, M | 1 |
| Alexander, RT; Saurette, M | 1 |
1 review(s) available for niacinamide and tenapanor
| Article | Year |
|---|---|
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Topics: Animals; Carrier Proteins; Chelating Agents; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Hyperphosphatemia; Isoquinolines; Niacinamide; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sulfonamides | 2018 |
1 other study(ies) available for niacinamide and tenapanor
| Article | Year |
|---|---|
Intestinal phosphate absorption: The paracellular pathway predominates?
Topics: Animals; Clinical Trials as Topic; Diet, Western; Electrochemistry; Enterocytes; Humans; Hyperphosphatemia; Intestinal Absorption; Isoquinolines; Mice; Mice, Knockout; Niacinamide; Organic Chemicals; Phosphates; Phosphorus, Dietary; Rabbits; Rats; Recombinant Proteins; Renal Insufficiency, Chronic; Sodium; Sodium-Hydrogen Exchanger 3; Sodium-Phosphate Cotransporter Proteins, Type IIb; Sodium-Phosphate Cotransporter Proteins, Type III; Sulfonamides | 2019 |